Reduction in the nephrotoxicity of amphotericin B when administered in 20% intralipid

Canadian Journal of Infectious Diseases

Volumn 8, Issue 3, 1997, Pages 157-160

  Salama, Suzette ^b   Rotstein, Coleman ^a  

^a HENDERSON GENERAL HOSPITAL   (Canada)

^b NONE

Author keywords

Amphotericin B; Candida species; Nephrotoxicity

Indexed keywords

AMPHOTERICIN B; CREATININE; DIPHENHYDRAMINE; GLUCOSE; INTRALIPID; PARACETAMOL; PETHIDINE; WATER;

ADULT; AGED; AQUEOUS SOLUTION; ARTICLE; CANDIDA ALBICANS; CLINICAL ARTICLE; CLINICAL TRIAL; CREATININE CLEARANCE; CROSSOVER PROCEDURE; DRUG FORMULATION; DRUG MIXTURE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MYCOSIS; NEPHROTOXICITY; ORAL DRUG ADMINISTRATION; PREMEDICATION;

EID: 0030812502     PISSN: 11802332     EISSN: None     Source Type: Journal    
DOI: 10.1155/1997/827297     Document Type: Article

References (16)

1. Bodey GP. The emergence of fungi as major hospital pathogens. J Hosp Infect 1988;11:411-26.
2. Beck-Sague CM, Jarvis WR, The National Nosocomial Infections Surveillance System. Secular trends in the epidemiology of nosocomial fungal infections in the United States 1980-1990. J Infect Dis 1993;167:1247-51.
3. Rex JH, Bennett JE, Sugar AM, et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. N Engl J Med 1994;331:1325-30.
4. Zuckerman JM, Tunkel AR. Itraconazole: A new triazole antifungal agent. Infect Control Hosp Epidemiol 1994;15:397-410.
5. Gallis H, Drew R, Pickard W. Amphotericin B: 30 years of clinical experience. Rev Infect Dis 1990;12:308-28.
6. Branch RA. Prevention of amphotericin B-induced renal impairment: A review on the use of sodium supplementation. Arch Intern Med 1988;148:2389-94.
7. Schmitt HJ. New methods of delivery of amphotericin B. Clin Infect Dis 1993;17(Suppl 2):S501-6.
8. Janknegt R, de Marie S, Bakker-Woudenberg AJM, Crommelin DJA. Liposomal and lipid formulations of amphotericin B: Clinical pharmacokinetics. Clin Pharmacokinet 1992;23:279-91.
9. Graybill JR. The future of antifungal therapy. Clin Infect Dis 1996;22(Suppl 2):S166-78.
10. Ringden O, Meunier F, Tollemar J, et al. Effect of amphotericin B encapsulated in liposomes (ambisome) in the treatment of invasive fungal infections in immunocompromised patients. J Antimicrob Chemother 1991;28(Suppl B):73-82.
11. Anaissie EJ, White M, Uzon O, et al. Amphotericin B lipid complex (ABLC) versus amphotericin B (AMB) for the treatment of hematogenous invasive candidiasis: A prospective randomized multicenter trial. Thirty-fifth Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, September, 17-20, 1995. (Abst)
12. Oppenheim BA, Herbrecht R, Kusne S. The safety and efficacy of amphotericin B colloidal dispersion in the treatment of invasive mycoses. Clin Infect Dis 1995;21:1145-53.
13. Chavanet PY, Carry I, Charlier N, et al. Trial of glucose versus fat emulsion in preparation of amphotericin B for use in HIV infected patients with candidiasis. BMJ 1992;305:921-5.
14. Caillot D, Casasnovas O, Solary E, et al. Efficacy and tolerance of an amphotericin B lipid (intralipid) emulsion in the treatment of candidaemia in neutropenic patients. J Antimicrob Chemother 1993;31:161-9.
15. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
16. Trissel LA. Amphotericin B does not mix with fat emulsion. Am J Health-Sys Pharm 1995;52:1463-4.